CAY10602 is primarily used in research settings as a potent and selective inhibitor of HDAC6, a histone deacetylase enzyme. Its application is significant in studying the role of HDAC6 in various cellular processes, including cell motility, stress response, and protein degradation. Researchers utilize CAY10602 to explore its potential therapeutic effects in diseases such as cancer, neurodegenerative disorders, and inflammatory conditions. By inhibiting HDAC6, it helps in understanding the mechanisms of protein aggregation and misfolding, which are critical in conditions like Alzheimer's and Parkinson's disease. Additionally, it is employed in preclinical studies to assess its efficacy in reducing tumor growth and metastasis, making it a valuable tool in the development of novel cancer therapies.